Express Scripts Zepbound Prior Authorization: 7 Rules [2026]

By The RX Index Editorial Team · Last verified: August 8, 2026

Primary sources: Express Scripts 2026 National Preferred Formulary and Exclusions (rev. 07/01/2026) · Cigna National Formulary Weight Loss GLP-1 Prior Authorization Policy CNF684 (revisions through 04/15/2026) · Cigna benefit-exclusion override policies CNF915, CNF908, and CNF950 · Express Scripts TRICARE PA form (03/12/2026) · CMS Medicare GLP-1 Bridge · FDA prescribing information

Affiliate disclosure: Some links on this page are affiliate links. If you start with a provider through one, we may earn a commission at no extra cost to you. It does not change our criteria, our sources, or what we tell you. We lead with plan checks, manufacturer options, and free steps before any paid provider.

The short answer

Express Scripts Zepbound prior authorization has two gates, not one. The device gate can stop the prescription before the clinical review begins. On the current 2026 Express Scripts National Preferred Formulary, Zepbound Pens are preferred, while Zepbound KwikPens and vials are excluded. Under the published standard commercial policy, the clinical gate is age 18+, at least three months of diet and behavior work, and a starting BMI of 30 or higher — or 27 or higher with a qualifying condition.

What changes the answer: your employer or health plan decides whether weight-loss drugs are part of your benefit. Some plans use stricter benefit-exclusion override rules. Sleep apnea runs on a separate track with different numbers. TRICARE and Medicare use completely different rulebooks.

Here is the part that explains a lot of confusing rejections: the clinical policy names all three Zepbound devices, while the current formulary excludes two of them. That does not mean the documents cancel each other out. It means you can meet the medical requirements and still fail because the exact product on the prescription is excluded.

The seven rules at a glance

We'll show you the device rule, the standard clinical criteria, the stricter override rules, and the right fix for each kind of denial.

Is this page for you?

Yes, if:

• Express Scripts (or Evernorth, or Cigna) runs your drug coverage
• Your Zepbound prescription is stuck waiting on prior authorization
• You got a denial letter and it just says "criteria not met"
• Your KwikPen used to fill and suddenly stopped
• Your approval expired and you need the renewal number
• You're going the sleep apnea route
• You have TRICARE and need the separate path
• Your letter says "benefit exclusion" and you need to know whether an override exists

No, if:

• You only want the cash price → see our Zepbound self-pay price guide
• You want to compare telehealth companies → see Zepbound providers that help with prior authorization
• You're on Medicare and want the $50 path → see the Medicare GLP-1 Bridge guide
• You're looking for compounded tirzepatide. Compounded tirzepatide is not brand-name, FDA-approved Zepbound. It is a separate access and risk decision, and we keep those paths separate on purpose.

First: which Zepbound is on your prescription?

This one table settles the first question faster than anything else on this page. We pulled it from the 2026 Express Scripts National Preferred Formulary Exclusions document, EXCL-NPF-26, revised July 1, 2026, and checked it again on August 8, 2026.

Here is the Weight Loss row from that document:

Excluded: Zepbound KwikPens and Zepbound vials. Preferred: liraglutide, Foundayo, Wegovy HD, Wegovy pens, Wegovy tablets, and Zepbound pens.

One drug. One molecule. Three devices. Two of them are off the current national list.

How to check yours in ten seconds: look at the pharmacy label or the prescription in your patient portal. If it says "KwikPen" or "vial," you have a product-level problem before the BMI review under the current NPF. Fixing it may be as simple as your prescriber sending a new prescription for the single-dose Zepbound Pen — if that device fits your treatment and your plan.

Do not ask the pharmacy to guess. Ask this exact question:

"Which Zepbound product and NDC did the prescription reject for, and was the rejection for prior authorization, formulary exclusion, or benefit exclusion?"

That answer tells you whether you need more medical records, a different device, or a different coverage path.

### The right GLP-1 provider isn't the same for everyone It depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Does Express Scripts cover Zepbound in 2026?

Zepbound Pens are preferred on the current 2026 Express Scripts National Preferred Formulary. Zepbound KwikPens and single-dose vials are excluded from it. Being on the national list is not the same as being covered by your plan — your employer or health plan still decides whether weight-loss medication is part of your benefit.

There are really two questions hiding inside "is it covered," and they have different answers and different fixes.

Question 1: Is the exact product on the national list? For the Zepbound single-dose Pen in 2026, yes. The current formulary lists ZEPBOUND PEN [INJ]. The July 1 exclusions document puts KwikPens and vials on the excluded side and Zepbound Pens on the preferred side.

Question 2: Did your employer or health plan include the weight-loss benefit? This is the one that stops people cold. Express Scripts says not every medication on its national list is covered by every prescription plan. Your plan can include obesity medication, exclude it, or use a special override program with tighter rules.

If the answer to question 2 is no, sending the same standard prior authorization again will not add the benefit. But do not stop at the words "benefit exclusion." Ask whether your plan has a benefit-exclusion override and which written policy controls it. Cigna publishes several such policies, and their BMI gates are stricter than the standard policy.

One myth worth killing carefully: the current national formulary uses an [SP] marker for specialty medications. Zepbound Pen does not carry that marker there. That means the current NPF does not label it [SP]; it does not prove that every employer plan puts it on the same tier or uses the same pharmacy rules.

What changed on July 1, 2026 — and why older guides can be wrong

Express Scripts re-issued its 2026 formulary documents with a July 1, 2026 revision date while keeping the same document numbers. In the April exclusions row, Zepbound vials were named. In the July row, Zepbound KwikPens and vials are both named as excluded.

That proves the July rule. It does not prove that every KwikPen was covered by every Express Scripts plan before July, because a national exclusions row is not a member's full benefit document.

This still matters for two reasons.

One: if your KwikPen suddenly stopped filling, the July revision may explain it. Do not assume the pharmacy made a mistake or that your medical approval disappeared. Ask for the reject code and the product NDC.

Two: the documents keep the same reference numbers. PRMT22157-26 and EXCL-NPF-26 can be replaced at the same web address during the year. A page can cite the right document number and still be reading an older copy.

How to tell which copy you're looking at: open the PDF and look at the footer. You should see EXCL-NPF-26 (07/01/2026) on the exclusions document. Anything older than July 1, 2026 is stale on the current KwikPen question.

The July 1 device reversal between Medicare and commercial coverage

Two systems took effect on the same date. They point in opposite directions because they serve different populations.

CMS lists six Zepbound NDCs for the Bridge, and all six are KwikPens. CMS also says pen needles are not covered by the Bridge and must be bought separately.

Express Scripts says the reverse for the current commercial NPF: KwikPens excluded, single-dose Pens preferred.

What that means for an actual human being: say you're 64, on an employer's Express Scripts plan, and doing well on Zepbound Pens. You turn 65, enroll in Part D, and meet the Bridge rules. Your prescription is now for the wrong device. It has to be rewritten as a KwikPen. If you do not know that going in, the first fill can reject even though the medicine and dose did not change.

Same drug. Same dose. Same week. Opposite device. If you're near that transition, our Medicare GLP-1 Bridge guide walks through the eligibility and pharmacy steps.

Express Scripts does not have one Zepbound rulebook. Find yours.

Express Scripts manages drug benefits for employers, Cigna-administered plans, TRICARE, and Medicare Part D plans. The rule that applies to you is set by your benefit and the reason Zepbound is prescribed — not by the logo alone.

People search for "the Express Scripts rule" as though there is one. There are several, and they disagree on the starting BMI, the number of qualifying conditions, how long you need to work on diet and behavior, whether you need to try another drug, and which device is covered.

The policy code matters. A person can meet the standard rule and still fail a stricter override. Do not let the call end with "your plan does not cover it." Ask:

"Does my plan offer a benefit-exclusion override for Zepbound? Which policy code or written criteria apply to me?"

About employer add-on rules

Some employers add requirements to their plan — a digital coaching program, a weigh-in schedule, extra documentation, or a different BMI gate. You may see someone online say, "Express Scripts made me sign up for a program." That may be completely true for them and completely irrelevant to you.

Do not assume someone else's requirement applies to you. Ask your plan directly:

"Is enrollment in a weight-management program a written requirement for my specific plan? What is the policy name or code, and where can I read it?"

If it is real, it should appear in your plan documents, the policy used for the review, or the denial letter.

Before you do anything else, write down four things: your plan lane, the exact Zepbound device, the indication, and the policy code. Those four answers separate a paperwork problem from a benefit problem.

What are the Express Scripts Zepbound prior authorization requirements?

Under the published standard Cigna National Formulary policy CNF684, an adult's first Zepbound request for weight management can be approved for 8 months when the patient is 18 or older, has completed at least 3 months of behavior change and diet work, and had a baseline BMI of 30 or higher — or 27 or higher with at least one listed health condition.

We read the current 33-page policy end to end on August 8, 2026. Its review date is July 9, 2025, with revisions through April 15, 2026. It names Foundayo, liraglutide, Wegovy products, and Zepbound in KwikPens, pens, and vials.

That last line matters. The clinical criteria name all three devices. The formulary separately excludes two of them. Passing the clinical review does not override a product exclusion.

This policy is a published standard for Cigna-administered plans. Your benefit document, a delegated vendor rule, or a plan-specific override can control instead.

First-time request: the exact checklist

Every one of these has to be true under standard policy CNF684:

• [ ] You are 18 or older
• [ ] You have completed at least 3 months of behavioral modification and dietary restriction
• [ ] Either your baseline BMI was 30 or higher
• [ ] Or your baseline BMI was 27 or higher and you had or have at least one qualifying condition
• [ ] Zepbound will be used with ongoing behavior change and a reduced-calorie diet
• [ ] Your exact product is covered by your plan, or an approved product exception is in place

If approved under this standard policy: 8 months. Not a year. Put the expiration date in your phone the day the letter arrives.

The 11 conditions that count at BMI 27–29.9

The standard policy lists eleven. If any one applies, a baseline BMI of 27 can meet that part of the rule:

Two details matter. First, the policy accepts a condition you had at baseline or currently have. A condition that improved after weight loss does not erase the fact that it was present at baseline.

Second, asthma, COPD, knee osteoarthritis, and PCOS are on the list. Those are easy to leave off if the office only checks for blood pressure, cholesterol, diabetes, and sleep apnea.

The baseline trap that can cost you a renewal

Throughout the policy, "baseline" means the point before any GLP-1 or GLP-1/GIP medicine.

In plain English: baseline means your weight and BMI before you started your first GLP-1 — not before you started Zepbound.

If you were on Wegovy for a year, lost 30 pounds, and then switched to Zepbound, your baseline is your weight before Wegovy. It is not your weight on the day you started Zepbound.

This cuts both ways, and both ways matter:

• Good news: your current BMI can be under 30 and you can still meet the published baseline rule.
• Bad news: your 5% renewal target is measured from that older starting weight too. If your office submits only your Zepbound start weight, the renewal math can be wrong.

Ask your prescriber's office for one specific thing: the weight and BMI from before your first GLP-1, with the date. That single record does more work than a fresh BMI without context.

What are the Express Scripts Zepbound renewal requirements?

Under standard policy CNF684, continuing Zepbound coverage for weight management is approved for 1 year when the patient is 18 or older, still meets the baseline BMI path, has lost at least 5% of baseline body weight, and continues the medicine with behavior change and a reduced-calorie diet. A patient who has not completed 8 months of initial therapy is reviewed under the initial criteria instead.

Do the math before your doctor's office does

Step 1: Starting weight × 0.05 = your 5% number Step 2: Starting weight − that number = the weight you need to be at or below

Worked example:

• Starting weight: 240 lb
• 5% of 240 = 12 lb
• Target: 228 lb or less

Another:

• Starting weight: 310 lb
• 5% of 310 = 15.5 lb
• Target: 294.5 lb or less

Remember: "starting weight" means before your first GLP-1 under this policy, not before Zepbound.

Put all four numbers in the renewal note:

1. Baseline date
2. Baseline weight
3. Current dated weight
4. Percent lost from baseline

Do not make the reviewer do the subtraction.

One nuance worth knowing. A January 8, 2025 revision removed the former short titration extension and changed continuation to a flat 1-year approval. If an older guide says the standard policy still gives an extra 4-month titration approval, it is out of date.

Are the sleep apnea rules different? Yes — easier in one way, harder in another

Zepbound has a separate FDA-approved use for moderate-to-severe obstructive sleep apnea in adults with obesity, and standard policy CNF684 runs it as its own pathway. The first approval is 1 year instead of 8 months, and the published criteria do not list a CPAP trial first. But renewal requires 10% weight loss instead of 5%.

What the sleep apnea path requires

• You are 18 or older
• Your baseline BMI was 30 or higher
• A sleep study shows moderate-to-severe obstructive sleep apnea and an apnea-hypopnea index, or AHI, of 15 or more events per hour
• You do not have central sleep apnea
• You do not have Cheyne-Stokes respiration
• Zepbound will be used with behavior change and a reduced-calorie diet

AHI is the number of apnea and hypopnea events per hour of sleep. An AHI of 15 to 29.9 is generally the moderate range. An AHI of 30 or more is the severe range.

There is no BMI-27-plus-condition door in this standard OSA path. The baseline BMI gate is 30.

Three policy-history changes that matter

We compared the revision history with the current text. These are not all loosenings. One made the rule stricter.

1. May 28, 2025 — the one-year sleep-study age limit was removed. The current standard policy still requires a qualifying sleep study, but it does not say that study must be from the past year.
2. December 3, 2025 — the central sleep apnea exclusion became stricter. The older wording used a 50% central-event threshold. The current wording excludes central sleep apnea without that threshold.
3. February 25, 2026 — the BMI rule changed from current BMI to baseline BMI before any GLP-1. This can help someone whose BMI fell below 30 after treatment, but the old pre-treatment record must be in the chart.

What this door does not list

On the published standard policy there is no named CPAP trial requirement, no PAP-adherence percentage, no sleep-specialist requirement, and no six-month lifestyle-program requirement for the sleep apnea path.

That does not stop a specific plan document from adding a rule. It does mean an office should not invent one or copy one from another payer without checking the policy that controls your plan.

The catch: renewal is twice as hard on the weight number

So the sleep apnea door gives you a longer first approval and does not list CPAP step therapy — then asks for twice the percentage loss to keep coverage under the standard policy. Neither is "better." They're different trades, and you should know which one you're signing up for before your prescriber picks the indication. The indication still has to match the real diagnosis and treatment purpose.

If sleep apnea is genuinely part of your picture, our Zepbound for sleep apnea coverage guide goes deeper on diagnosis and plan routing.

What should my doctor send with the prior authorization?

A person can meet the rule and still be denied when the record leaves out the baseline date, qualifying condition, lifestyle history, exact device, or renewal math. The packet should make every required answer visible without forcing the reviewer to hunt through years of notes.

Here's the whole packet. Print this section or send it to your prescriber's office.

Copy this message to your prescriber's office

"Hi — my Zepbound prior authorization is for [weight management / sleep apnea] and this is [my first request / a renewal]. Could you please confirm the submission includes my baseline weight and BMI from before my first GLP-1 with the date, my qualifying condition if needed, the required lifestyle documentation, the exact Zepbound product, and the policy or override criteria my plan is using? For a renewal, please include my current dated weight and the percent lost from baseline. Could you also send me the submission date and case number? Thank you."

One thing not to do

Do not ask anyone to add a diagnosis you do not have, and do not add one yourself. Prescribers attest that the information is accurate. The documentation also has to support the diagnosis.

What you should do is make sure nothing true gets left off. Asthma, PCOS, COPD, and knee osteoarthritis are on the standard qualifying list and can be missed when an office uses a shorter checklist.

Before the office submits, read our broader guide to getting insurance to cover a GLP-1 and compare its packet checklist with your own chart.

How is the prior authorization submitted, and how long does it take?

Prescribers submit Express Scripts coverage reviews electronically, through systems including EviCore, Surescripts, and CoverMyMeds. Express Scripts says nearly all reviews are finished within two days of receiving complete information from the prescriber, and some electronic decisions come back within minutes. Members can track status by signing in to their Express Scripts account and opening Prior Authorizations.

Where the request actually goes

Express Scripts directs coverage reviews to esrx.com/PA. Prescriber offices can use their electronic prior authorization workflow. If an office needs help with a request, Express Scripts lists the prescriber line at 800-753-2851.

That number is for prescribers. As a member, use the number on the back of your prescription card for your plan-specific benefit, reject code, and status.

Only your doctor supplies the clinical information in a normal review. Express Scripts says a pharmacist may supply information in some urgent cases. You cannot complete the clinical submission yourself, but you can make sure the office has the right dates and records.

The four dates that matter

People get frustrated because they are counting from the wrong day. Track these separately:

1. The date the prescription was written
2. The date the prior authorization was actually submitted
3. The date Express Scripts says it received complete information
4. The decision date

The stated two-day turnaround is tied to complete information, not the day the prescription was written. A request that looks "pending" for weeks can be sitting before submission or waiting on a missing field.

If it has been more than a couple of business days

Call the number on your card and ask these five questions in this order:

1. "Has a prior authorization request for Zepbound been received for me?"
2. "What date was it considered complete?"
3. "Is it waiting on my prescriber?"
4. "What exact document or field is missing?"
5. "Can I get the case number and a reference number for this call?"

Then send the exact missing item to the office. Not "they need more information" — the specific field.

If you need medication now

Express Scripts says a pharmacist may be able to provide a small supply while a review is pending, though you may have to pay full price. Ask the pharmacist what is possible for your prescription and plan.

A prescriber can also ask for faster handling when a request is urgent. The plan applies its urgent-review rules; do not label a request urgent unless the prescriber believes delay could meet that standard.

Why was my Zepbound prior authorization denied?

A Zepbound denial from Express Scripts is not one problem with one fix. It can be missing information, criteria not met, the wrong device, an expired approval, a plan-specific extra rule, a standard benefit exclusion, or an override request reviewed under the wrong policy. Sending the same form again only helps when the first form was incomplete or wrong.

Find your denial in this table.

The distinction that saves you weeks

There are four different "no" answers, and people burn months confusing them:

• A prior authorization denial means the clinical review did not pass under the policy used. It may be fixable with missing documentation, corrected facts, or an appeal.
• A formulary exclusion means the exact product is off the list. It may be fixable with a product switch or coverage review.
• A benefit exclusion means the standard plan does not include the category. A normal PA cannot create that benefit.
• A benefit-exclusion override is a separate written door some plans offer. It usually uses stricter BMI and comorbidity rules than the standard policy.

Here is the comparison nobody should make you assemble from four separate PDFs:

Not every plan uses these policies. That is the point. The exact code on your review changes the answer.

Use this script:

"I'm calling about Zepbound, case number [X]. Was this reviewed as a standard prior authorization, a formulary exclusion, a benefit exclusion, or a benefit-exclusion override? Which exact policy code was used? Does my plan use CNF684, CNF915, CNF908, CNF950, or another written rule? Which criterion was not met, and what document would satisfy it? Can my prescriber correct and resubmit, or does this need an appeal? Please give me a reference number for this call."

The document that overrides the policy

The standard policy says the member's benefit plan document controls when it conflicts with the coverage policy. Its plainest line is that a customer's plan document "always supersedes" the standard coverage policy.

That's the honest bottom line, and it comes from the policy itself. This page gives you the published baseline and published override paths. Your benefit document and the policy actually assigned to your case decide your result.

Your appeal rights and the deadlines

For many employer group health plans governed by federal claims rules:

• You generally get at least 180 days from the denial notice to file an appeal.
• An initial pre-service claim is generally decided within 15 days, with one 15-day extension allowed in certain cases.
• A pre-service appeal is generally decided within 30 days for a one-level appeal process, or 15 days per level for a two-level process.
• An urgent-care appeal is generally decided within 72 hours.

Your denial letter gives the actual route and deadline. Medicare, TRICARE, government plans, church plans, and state-regulated coverage can use different procedures.

For federal urgent-claim rules, a physician with knowledge of the condition can determine that the claim involves urgent care under the applicable standard. Do not assume every delayed weight-management request qualifies. Ask the prescriber to make that call based on your health and the rule.

Also useful: our formulary exception guide and, after internal appeal rights are used, our guide to external review for a GLP-1 denial.

What will Zepbound cost if it is approved — and what if it is not covered?

Express Scripts does not publish one Zepbound copay for every member because the employer or health plan sets the tier, deductible, coinsurance, and pharmacy rules. One option worth asking about: Evernorth offers participating employers a benefit design that caps the member cost for Wegovy and Zepbound at no more than $200 per month.

The optional $200 cap to ask about

Evernorth announced the option on May 21, 2025. For participating employer plans, it limits the member cost for Wegovy and Zepbound to no more than $200 per month, and that amount counts toward the annual deductible. Evernorth says the option can save a member up to about $3,600 per year compared with buying directly from the manufacturer.

The catch: the employer has to choose the option. It is not automatic and it is not universal.

Ask HR or your plan:

"Has our plan enrolled in Evernorth's member-cost cap for Wegovy and Zepbound? If yes, what fills, pharmacies, and benefit rules does it cover?"

If the answer is yes, the cap applies under the plan's terms. It does not erase prior authorization, formulary, or eligibility rules.

This sits inside Evernorth's broader EncircleRx program. Evernorth reports more than 9 million enrolled lives and $200 million in health-plan savings since 2024. Those are company-reported figures, not an independent audit.

The honest cost ladder, cheapest path first

If your plan will not pay, here is the order to check — and we're going to be straight with you about which paths pay us and which do not.

1. Your plan covers it — check the copay, deductible, and whether the $200 cap applies. This is usually the first price to compare.
2. Manufacturer savings card — available to some people with eligible commercial insurance. See our Zepbound savings card guide. We earn nothing here.
3. LillyDirect self-pay — as verified August 8, 2026, Lilly lists $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg under the current offer. To keep the offer price on 7.5 mg through 15 mg, the refill must meet Lilly's 45-day timing rule. If that window is missed, Lilly currently lists $499 for 7.5 mg and $699 for 10 mg through 15 mg; the 2.5 mg and 5 mg prices remain $299 and $399. If you already have a prescriber, this usually costs less than adding a telehealth membership. We earn nothing here.
4. Telehealth with FDA-approved Zepbound — you pay a membership on top of the medication in exchange for a prescriber, ongoing care, coverage checking, and help with paperwork. Compare the total, not just the first-month membership.

Manufacturer prices and offer terms can change. Check the current Lilly page before paying.

If your plan excludes weight-loss drugs

Do not send the same standard PA again. Ask whether your plan has a benefit-exclusion override and which policy code applies.

If the plan confirms there is no override, a standard PA cannot add a benefit the plan did not buy. What can change a true exclusion: a future plan-design decision, open enrollment, a different employer plan, or an applicable coverage mandate. What cannot change it: resending the same clinical form.

If an override exists, compare your record with the exact rule. The published BEO and EncircleRx paths can require a baseline BMI of 32 or 35, or two qualifying conditions at BMI 27, instead of the standard one-condition rule.

One honest limitation before we recommend anyone

Ro cannot make Express Scripts say yes. It cannot override your plan document, turn an excluded device into a covered device, or guarantee approval.

Ro does say its insurance concierge can gather and submit prior authorization paperwork, communicate with the insurer, and help with an appeal for supported medications. That is different from its free checker. The free checker contacts the insurer only to report coverage; it does not request treatment or write a prescription.

The checker currently reports coverage for the Ozempic pen, Wegovy pen, and Zepbound single-dose Pen. It does not check Zepbound KwikPen coverage. That limitation matters on this page because KwikPen is the device causing the new formulary problem.

If the KwikPen or vials are your only issue, do not buy a membership before asking your current prescriber whether the single-dose Pen works for you and is covered. You can also compare how to get Zepbound KwikPen online and Zepbound self-pay prices. If you're eligible for the Medicare Bridge, the $50 program beats every cash option here.

What Ro actually costs and does

The free coverage check is the low-risk move. It does not request treatment or write a prescription. It contacts your insurer and sends a report on whether the supported Zepbound Pen is covered and whether prior authorization is required.

*→ Check your Zepbound Pen coverage free with Ro (affiliate link)***

We are not recommending compounded tirzepatide on this page. You came here trying to get FDA-approved Zepbound covered. A compounded tirzepatide product is not FDA-approved, and FDA does not review a compounded drug for safety, effectiveness, or quality before it is marketed. That is a different decision — not a silent substitute for a brand-name denial.

How is TRICARE different?

TRICARE uses its own Zepbound prior authorization form, dated March 12, 2026. The weight-management path requires six months of documented diet and behavior work plus a three-month trial of a listed generic weight-loss drug unless an exception applies. The obstructive sleep apnea path is different and does not use that generic-drug step.

If your card says TRICARE, skip the commercial checklist above. It doesn't apply to you.

TRICARE weight-management path

• Zepbound is adults-only. The form routes ages 12–17 to Wegovy instead.
• Baseline BMI is 30 or higher, or 27–29.9 with a listed condition.
• You need six months of behavior modification and dietary restriction, with failure to reach the desired weight loss.
• You need a three-month trial of one listed generic drug — phentermine, benzphetamine, diethylpropion, or phendimetrazine — with less than 5% loss, unless there is a documented contraindication or adverse reaction.
• The form has hard stops for pregnancy, use of another GLP-1 at the same time, and a personal or family history of medullary thyroid carcinoma or MEN 2.
• Initial approval is 12 months. Adult renewal requires at least 5% loss from baseline after full titration.

TRICARE sleep-apnea path

• The form is for the Zepbound Pen Injector.
• The patient must be an adult.
• Baseline BMI must be 30 or higher.
• The sleep study must show an AHI of at least 15.
• The six-month behavior and diet requirement still applies.
• The generic oral weight-loss drug trial does not apply to this OSA route.
• Renewal asks whether OSA symptoms improved based on an improved AHI; it does not copy the standard commercial 10% renewal rule.

TRICARE says weight-loss drug coverage is limited to eligible TRICARE Prime and TRICARE Select beneficiaries. Your current eligibility and the current form control.

Full walkthrough: Does TRICARE cover Zepbound?

How is Medicare different?

Basic Medicare Part D does not cover Zepbound when it is used only for weight loss. Zepbound can be covered through Part D for a Part D-covered indication such as moderate-to-severe obstructive sleep apnea, subject to the plan's formulary and prior authorization. From July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge offers eligible Part D members a $50 monthly copay for weight management — and Zepbound is available there only as the KwikPen.

Some enhanced Part D plans may offer excluded drugs as supplemental benefits, so check your plan before treating the basic Part D rule as the end of the answer.

Who qualifies for the $50 Medicare GLP-1 Bridge?

You must have an eligible form of Medicare drug coverage, be at least 18, use the drug for weight management, and meet one of these clinical paths at the time you started GLP-1 therapy:

• BMI 35 or higher, or
• BMI 30 or higher plus heart failure with preserved ejection fraction, uncontrolled high blood pressure despite two blood-pressure medicines, or chronic kidney disease stage 3a or higher, or
• BMI 27 or higher plus prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease

You are not eligible for the Bridge if your GLP-1 is already covered through your Part D plan. CMS also routes type 2 diabetes, moderate-to-severe sleep apnea, and noncirrhotic MASH through Part D rather than the Bridge.

Three device and cost facts matter:

1. The Bridge covers Zepbound KwikPen only. It does not offer the single-dose Pen or vials.
2. The copay is $50 for a one-month supply. The Part D deductible does not apply.
3. The $50 does not count toward Part D true out-of-pocket costs or the annual out-of-pocket limit. Pen needles are not covered by the Bridge.

The Bridge runs outside the normal Part D payment flow and uses its own central prior authorization process. The prescriber sends the prescription to the pharmacy first; the pharmacy claim starts the Bridge review. CMS says an approval stays valid through December 31, 2027, including dose changes, unless you switch GLP-1 drugs. CMS also says there is no formal Bridge appeal process, but a prescriber can resubmit corrected, updated, or additional information after a denial.

Details: Does Medicare cover Zepbound? and the Medicare GLP-1 Bridge program guide.

How to fact-check anything you read about this, including us

Express Scripts can publish updated formulary files at the same web addresses and keep the same document numbers. A page can name the right file and still use the wrong version. Check the footer date, the exact product, and the policy code.

Three steps, about two minutes:

1. Open the current National Preferred Formulary Exclusions PDF from Express Scripts.
2. Look at the footer for the version date — for this page, we verified 07/01/2026.
3. Search for "ZEPBOUND" and read the Weight Loss row yourself.

Then open the policy used for your own review. Do not assume CNF684 applies just because it is the standard public policy. A denial may name CNF915, CNF908, CNF950, a delegated vendor policy, or an employer-specific requirement.

Five claims to verify before you trust a guide

• "Zepbound Pens are excluded and vials are preferred." That is backwards under the July 1, 2026 national exclusions row. Zepbound Pens are preferred; KwikPens and vials are excluded.
• "Zepbound is always a specialty-tier drug at Express Scripts." The current NPF does not put the [SP] marker next to Zepbound Pen. A member's plan can still use its own tier and pharmacy rules.
• "The standard policy requires 12 consecutive weeks and a BMI from the past 30 days." CNF684 says at least three months of behavior and diet work and uses baseline BMI before any GLP-1.
• "Express Scripts denies a specific percentage of Zepbound requests" or "a specific percentage of appeals wins." The primary documents used for this page do not publish a national Zepbound-specific approval, denial, or appeal-success rate. Do not trust a precise number without a named dataset.
• "All weight-loss GLP-1 drugs are excluded from the 2026 base formulary." The current NPF lists preferred products, including Zepbound Pens. Your plan can still exclude the benefit.

Every one of those is checkable from the primary documents below.

What we actually verified

We opened the current documents below on August 8, 2026. The formulary and policy facts on this page come from primary sources, not another insurance blog.

What these documents cannot tell you — and no public guide can:

• Your exact tier, deductible, coinsurance, or copay
• Whether your employer bought the standard weight-loss benefit
• Whether your plan uses a benefit-exclusion override
• Whether your plan added a program or delegated vendor requirement
• Whether your individual request will be approved

Those answers live in your plan documents, your denial letter, the policy code assigned to your case, and your Express Scripts account.

How this page was made: The RX Index Editorial Team read each source above, compared the clinical criteria with the formulary product rules, and translated them into a member checklist. We did not submit your prior authorization, and the published criteria do not guarantee coverage. We recheck this page because the formulary documents can be revised during the year.

A quick safety note: Zepbound is a prescription medicine. Its boxed warning says tirzepatide caused thyroid C-cell tumors in rats; whether it causes them in humans is unknown. Zepbound is contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN 2. Only a licensed clinician can decide whether it is right for you. This page explains coverage rules; it is not medical advice and does not replace the FDA label or your doctor.

Frequently asked questions

Does Express Scripts cover Zepbound? Some Express Scripts plans cover the Zepbound single-dose Pen with prior authorization. KwikPens and vials are excluded from the current 2026 National Preferred Formulary, and some plans exclude weight-loss drugs or use a stricter override. Check the exact device, benefit, and policy code.

What BMI do I need for Zepbound with Express Scripts? Standard policy CNF684 uses a baseline BMI of 30 or higher, or 27 or higher with at least one of eleven listed conditions. Published override policies can use BMI 32 or 35, or require two conditions at BMI 27. Your policy code decides which rule applies.

How long is the first approval? Under standard commercial policy CNF684, 8 months for weight management and 1 year for sleep apnea. TRICARE uses a 12-month first approval. Your approval letter has the actual expiration date.

How much weight do I have to lose to renew? Under standard CNF684, at least 5% of baseline body weight on the weight-management path and at least 10% on the sleep-apnea path. TRICARE uses different continuation questions. Use the rule named in your approval or denial.

My BMI is under 30 now. Can I still meet the standard rule? Yes, the standard policy uses baseline BMI from before your first GLP-1. Your plan may use a different policy, so send the older dated record and confirm the policy code.

Does Express Scripts require step therapy for Zepbound? Standard commercial policy CNF684 does not list a drug step for Zepbound. The TRICARE weight-management route does require a three-month trial of a listed generic drug unless an exception applies. The TRICARE OSA route does not use that generic step. An employer plan can add its own rule.

Can I submit the prior authorization myself? Not the clinical submission. Express Scripts says the doctor supplies the clinical information in a normal review, with a pharmacist able to provide information in some urgent cases. You can track the request, provide records to the office, and get the case number.

How long does an Express Scripts prior authorization take? Express Scripts says nearly all reviews finish within two days after complete prescriber information arrives, and some electronic decisions return within minutes. A long delay can mean the request was not submitted, the information is incomplete, or a plan-specific review is still open.

Why did my Zepbound KwikPen stop being covered? The July 1, 2026 national exclusions row explicitly names Zepbound KwikPens as excluded. That change may explain a new product-level rejection, but ask for the reject code because your plan can have its own rules.

Is Zepbound covered for sleep apnea? Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Standard policy CNF684 has a separate path requiring baseline BMI 30 or higher and a sleep study with AHI 15 or higher. Your plan still decides coverage.

Can I appeal a benefit exclusion? A normal clinical PA cannot add an excluded benefit. But some plans offer a separate benefit-exclusion override. Ask whether your plan uses CNF915, CNF908, CNF950, or another written override before assuming the answer is final.

Why do I need a new prior authorization when I was already approved? Approvals expire, plans change, and the product list can change. A renewal needs the correct baseline, current dated weight, percent lost, and the criteria from the policy that applies at renewal.

Does Express Scripts require Omada or another program? Not as a universal published rule. Some employers add a program requirement. Ask for the written rule and the policy name instead of relying on another member's experience.

Can I get a temporary supply while I wait? Express Scripts says a pharmacist may be able to provide a small supply while the review is pending, though you may have to pay full price. Ask the pharmacist about your exact prescription and plan.

Does TRICARE use the same rules? No. TRICARE uses a separate March 12, 2026 form. Its weight-management path uses six months of lifestyle documentation and a three-month generic drug trial unless an exception applies. Its OSA route does not use that generic step.

Can Ro guarantee approval? No. Ro says its concierge can work on prior authorization paperwork and appeals, but it cannot override plan rules or guarantee coverage. Its free checker currently checks Zepbound single-dose Pen, not KwikPen.

Can I pay cash and skip prior authorization? Yes. Prior authorization decides whether insurance pays. With a valid prescription, you can pay cash for an available product instead. Cash payment does not create coverage or change the denial.

Is compounded tirzepatide the same as Zepbound? No. Zepbound is an FDA-approved brand-name drug. A compounded tirzepatide product is not FDA-approved, and FDA does not pre-review it for safety, effectiveness, or quality. Do not treat it as an invisible swap for a Zepbound coverage denial.

One last thing

If you take only one action from this page, make it this: look at your prescription and confirm which Zepbound device it names. Under the current commercial National Preferred Formulary, the preferred product is the single-dose Zepbound Pen. KwikPen and vials are excluded.

That check can stop you from fighting a clinical denial when the first problem is the product.

Then get your baseline weight and BMI from before your first GLP-1, with the date. After that, get the policy code. Those three things — the right device, the right starting number, and the right rulebook — are what turn a vague rejection into a specific next step.

Still not sure which GLP-1 path fits your insurance, state, and budget? Take our free 60-second matching quiz.